Facebook Twitter LinkedIn
PathKey
PAthkey
August 4, 2026

PathKey.AI (ASX:PKY): Chip design in the age of AI

PathKey.AI (ASX:PKY, PathKey) is an ASX-listed Artificial Intelligence (AI) company that recently acquired Singapore-based Chipforge, which aims to speed up the design process for semiconductors by using AI agents to undertake the time-intensive and costly part of the chip design process for this US$1 trillion industry. PathKey is simultaneously commercialising TrialKey, an AI-driven clinical trial […]
Read More
SRJ Technologies
July 27, 2026

SRJ Technologies (ASX:SRJ): An emerging asset integrity play

SRJ Technologies (ASX: SRJ) is an asset integrity technology provider whose robots and drones help inspect oil and gas infrastructure. SRJ has three complementary business units (ACE, EAS and MEAS) that form a unified, technology-enabled asset integrity platform covering the entire asset maintenance cycle (inspection, maintenance and repair). The selling point to clients is that […]
Read More
AFT Pharmaceuticals
July 25, 2026

AFT Pharmaceuticals (ASX:AFP): A broader pipeline is emerging

AFT Pharmaceuticals (ASX:AFP) is a New Zealand-based specialty pharmaceutical company that offers investors both the stability established, cash-generative Maxigesic franchise sold across 87 countries but also significant upside from a pipeline of new commercial opportunities that the market is ascribing little to no value to. AFT is a well-established business AFT has increased its revenue […]
Read More
ECT
July 23, 2026

Environmental Clean Technologies (ASX:ECT): Actually destroying the new asbestos

Environmental Clean Technologies (ASX:ECT) is building a PFAS destruction platform that can destroy PFAS while meeting tightening regulatory expectations. Destroying PFAS chemicals, instead of just removing or treating them ECT has a Rapid Electrothermal Mineralisation (REM) system, derived from Flash Joule Heating (FJH) that is for both in-situ and ex-situ destruction of PFAS, having licensed […]
Read More
Prescient Therapeutics
June 25, 2026

Prescient Therapeutics (ASX:PTX): Phase 2 momentum is building!

Oncology developer Prescient Therapeutics (ASX:PTX) is developing PTX-100 and is in the middle of a Phase 2 trial. PTX-100, is the world’s first GGTase-1 (geranylgeranyl transferase-1) inhibitor to enter clinical development, and it is currently the only drug of its kind being evaluated against relapsed/refractory cutaneous T-Cell Lymphoma (r/r CTCL) – an aggressive form of […]
Read More
Register for the Conference